As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -1.44 -1.44 |
83%
83%
|
|
| EBIT (Operating Income) EBIT | -1.44 -1.44 |
83%
83%
|
|
| Net Profit | -1.57 -1.57 |
82%
82%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
| Head office | Bahamas |
| CEO | Paul Averback |
| Employees | 18 |
| Founded | 1995 |
| Website | nymox.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


